Status:
ACTIVE_NOT_RECRUITING
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
Lead Sponsor:
Centre Jean Perrin
Collaborating Sponsors:
International Cancer Research Group, United Arab Emirates
Conditions:
Breast Cancer Female
BRCA1 Mutation
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to validate the interest of broadband spectroscopy analysis (femto/attosecond by infrared laser) on liquid biopsies in breast cancer screening.
Detailed Description
Each patient will have one or more liquid biopsy during the follow-up according to the cohort and have a mammogram at the same time. Biopsies will be analysed by broadband spectroscopy in order to co...
Eligibility Criteria
Inclusion
- \*For all participants :
- Adult woman capable of giving informed consent to research participation
- Affiliation to the French social security system
- \>For Control cohort:
- Woman participating in organised screening or benefiting from individual follow-up, eligible as such for a mammogram
- \>For Patient cohort:
- woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at inclusion and before any cancer treatment
- \>For Exploratory cohort:
- woman carrying the BRCA1/2 mutation, followed according to standard recommendations or
- woman carrying the BRCA1/2 mutation suffering from in situ BC discovered on biopsy and histologically confirmed
Exclusion
- For all participants :
- Refusal to participate
- Reluctant or unable to comply with study requirements
- Pregnant or breastfeeding woman
- History of breast cancer
- For Patient cohort
- \- Patients with Stage III/IV or Bilateral Breast Cancer
- For Control cohort:
- Invasive breast cancer suspected at mammography before liquid biopsy\*
- Mammography classified ACR3 or ACR4
- For Exploratory cohort:
- Concomitant breast cancer
- At inclusion visit, woman for whom an invasive breast cancer will be suspected at mammography will be include in Patient cohort after an histological proof of cancer
Key Trial Info
Start Date :
May 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2029
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT04273542
Start Date
May 31 2021
End Date
May 1 2029
Last Update
September 10 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean PERRIN
Clermont-Ferrand, Puy de Dome, France, 63011
2
La Chataigneraie (Selimed 63)
Beaumont, Puy de Dôme, France, 63110
3
Pôle Santé République
Clermont-Ferrand, Puy de Dôme, France, 63000
4
Institut de Cancérologie de l'Ouest
Angers, France